Associations between baseline risk factors and vertebral fracture risk in the multiple outcomes of raloxifene evaluation (MORE) study

被引：81

作者：

Johnell, O

Kanis, JA

Black, DM

Balogh, A

Poor, G

Sarkar, S

Zhou, CM

Pavo, I

机构：

[1] Malmo Gen Hosp, Dept Orthopaed, S-21401 Malmo, Sweden

[2] Univ Sheffield, WHO, Ctr Metab Bone Dis, Sheffield, S Yorkshire, England

[3] Univ Calif San Francisco, Div Clin Epidemiol, San Francisco, CA 94143 USA

[4] Univ Debrecen, Med & Hlth Sci Ctr, Dept Obstet & Gynecol, Debrecen, Hungary

[5] Natl Inst Rheumatism & Physiotherapy, Budapest, Hungary

[6] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2004年 / 19卷 / 05期

关键词：

raloxifene; postmenopausal osteoporosis; risk factors; vertebral fracture;

D O I：

10.1359/JBMR.040211

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Different risk factors may influence the effectiveness of osteoporosis therapies. The interaction of 30 baseline risk factors and the effectiveness of raloxifene in the MORE study were assessed. The efficacy of raloxifene in reducing vertebral fractures is largely independent of the presence of clinical risk factors for osteoporotic fractures.

引用

页码：764 / 772

页数：9

共 38 条

[1]

Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis [J].